Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis

The Italian experience

Angelo Ghezzi, Maria Pia Amato, Pietro Annovazzi, Marco Capobianco, Paolo Gallo, Loredana La Mantia, Maria Giovanna Marrosu, Vittorio Martinelli, Nicoletta Milani, Lucia Moiola, Francesco Patti, Carlo Pozzilli, Maria Trojano, Mauro Zaffaroni, Giancarlo Comi, I. L. Simone, Elisabetta Di Monte, R. Ardito, S. Stecchi, C. Scandellari & 26 others M. G. Marrosu, G. Spinicci, F. Patti, E. D'Amico, E. Portaccio, S. Lori, G. F. Costantino, V. Pilato, M. Zaffaroni, A. Bellantonio, R. Fantozzi, C. Milanese, E. Scarpini, M. De Riz, P. Sola, E. Merelli, A. Guerra, P. Perini, M. Atzori, R. Bergamaschi, P. Veggiottii, L. Prosperini, A. Bertolotto, M. Capobianco, S. Malucchi, P. Cavalla

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The main objective of this study is to evaluate the effect of immunomodulatory agents (IMAs) (Interferon-Beta, Glatiramer Acetate) in a large cohort of multiple sclerosis (MS) patients with disease onset in childhood or adolescence, treated before 16 years of age, after a long-term follow-up. A total of 130 patients were identified, 77 were treated with Avonex, 39 with Rebif/Betaferon, 14 with Copaxone. After a mean (SD) treatment duration of 53.6 ± 27.0, 59.9 ± 39.5 and 74.6 ± 35.5 months, respectively, the relapse rate decreased significantly. The final EDSS score was unchanged with respect to the initial score. Similar results were also observed in subjects who continued a long-term follow-up after they were included in an observational study in 2004, and in subjects who were treated before 12 years of age. The frequency of clinical and laboratory adverse events was similar to that observed in adult patients. To conclude, IMAs were effective and well tolerated in paediatric patients with MS.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalNeurological Sciences
Volume30
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Multiple Sclerosis
Interferon-beta
Therapeutics
Observational Studies
Pediatrics
Recurrence
Glatiramer Acetate
Interferon beta-1a

Keywords

  • Adolescence
  • Childhood
  • Glatiramer acetate
  • Immunomodulatory agents
  • Interferon-beta
  • Multiple sclerosis
  • Paediatric multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Ghezzi, A., Amato, M. P., Annovazzi, P., Capobianco, M., Gallo, P., La Mantia, L., ... Cavalla, P. (2009). Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: The Italian experience. Neurological Sciences, 30(3), 193-199. https://doi.org/10.1007/s10072-009-0083-1

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis : The Italian experience. / Ghezzi, Angelo; Amato, Maria Pia; Annovazzi, Pietro; Capobianco, Marco; Gallo, Paolo; La Mantia, Loredana; Marrosu, Maria Giovanna; Martinelli, Vittorio; Milani, Nicoletta; Moiola, Lucia; Patti, Francesco; Pozzilli, Carlo; Trojano, Maria; Zaffaroni, Mauro; Comi, Giancarlo; Simone, I. L.; Di Monte, Elisabetta; Ardito, R.; Stecchi, S.; Scandellari, C.; Marrosu, M. G.; Spinicci, G.; Patti, F.; D'Amico, E.; Portaccio, E.; Lori, S.; Costantino, G. F.; Pilato, V.; Zaffaroni, M.; Bellantonio, A.; Fantozzi, R.; Milanese, C.; Scarpini, E.; De Riz, M.; Sola, P.; Merelli, E.; Guerra, A.; Perini, P.; Atzori, M.; Bergamaschi, R.; Veggiottii, P.; Prosperini, L.; Bertolotto, A.; Capobianco, M.; Malucchi, S.; Cavalla, P.

In: Neurological Sciences, Vol. 30, No. 3, 2009, p. 193-199.

Research output: Contribution to journalArticle

Ghezzi, A, Amato, MP, Annovazzi, P, Capobianco, M, Gallo, P, La Mantia, L, Marrosu, MG, Martinelli, V, Milani, N, Moiola, L, Patti, F, Pozzilli, C, Trojano, M, Zaffaroni, M, Comi, G, Simone, IL, Di Monte, E, Ardito, R, Stecchi, S, Scandellari, C, Marrosu, MG, Spinicci, G, Patti, F, D'Amico, E, Portaccio, E, Lori, S, Costantino, GF, Pilato, V, Zaffaroni, M, Bellantonio, A, Fantozzi, R, Milanese, C, Scarpini, E, De Riz, M, Sola, P, Merelli, E, Guerra, A, Perini, P, Atzori, M, Bergamaschi, R, Veggiottii, P, Prosperini, L, Bertolotto, A, Capobianco, M, Malucchi, S & Cavalla, P 2009, 'Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: The Italian experience', Neurological Sciences, vol. 30, no. 3, pp. 193-199. https://doi.org/10.1007/s10072-009-0083-1
Ghezzi, Angelo ; Amato, Maria Pia ; Annovazzi, Pietro ; Capobianco, Marco ; Gallo, Paolo ; La Mantia, Loredana ; Marrosu, Maria Giovanna ; Martinelli, Vittorio ; Milani, Nicoletta ; Moiola, Lucia ; Patti, Francesco ; Pozzilli, Carlo ; Trojano, Maria ; Zaffaroni, Mauro ; Comi, Giancarlo ; Simone, I. L. ; Di Monte, Elisabetta ; Ardito, R. ; Stecchi, S. ; Scandellari, C. ; Marrosu, M. G. ; Spinicci, G. ; Patti, F. ; D'Amico, E. ; Portaccio, E. ; Lori, S. ; Costantino, G. F. ; Pilato, V. ; Zaffaroni, M. ; Bellantonio, A. ; Fantozzi, R. ; Milanese, C. ; Scarpini, E. ; De Riz, M. ; Sola, P. ; Merelli, E. ; Guerra, A. ; Perini, P. ; Atzori, M. ; Bergamaschi, R. ; Veggiottii, P. ; Prosperini, L. ; Bertolotto, A. ; Capobianco, M. ; Malucchi, S. ; Cavalla, P. / Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis : The Italian experience. In: Neurological Sciences. 2009 ; Vol. 30, No. 3. pp. 193-199.
@article{a6516c7c03c4474fb03172d2be469177,
title = "Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: The Italian experience",
abstract = "The main objective of this study is to evaluate the effect of immunomodulatory agents (IMAs) (Interferon-Beta, Glatiramer Acetate) in a large cohort of multiple sclerosis (MS) patients with disease onset in childhood or adolescence, treated before 16 years of age, after a long-term follow-up. A total of 130 patients were identified, 77 were treated with Avonex, 39 with Rebif/Betaferon, 14 with Copaxone. After a mean (SD) treatment duration of 53.6 ± 27.0, 59.9 ± 39.5 and 74.6 ± 35.5 months, respectively, the relapse rate decreased significantly. The final EDSS score was unchanged with respect to the initial score. Similar results were also observed in subjects who continued a long-term follow-up after they were included in an observational study in 2004, and in subjects who were treated before 12 years of age. The frequency of clinical and laboratory adverse events was similar to that observed in adult patients. To conclude, IMAs were effective and well tolerated in paediatric patients with MS.",
keywords = "Adolescence, Childhood, Glatiramer acetate, Immunomodulatory agents, Interferon-beta, Multiple sclerosis, Paediatric multiple sclerosis",
author = "Angelo Ghezzi and Amato, {Maria Pia} and Pietro Annovazzi and Marco Capobianco and Paolo Gallo and {La Mantia}, Loredana and Marrosu, {Maria Giovanna} and Vittorio Martinelli and Nicoletta Milani and Lucia Moiola and Francesco Patti and Carlo Pozzilli and Maria Trojano and Mauro Zaffaroni and Giancarlo Comi and Simone, {I. L.} and {Di Monte}, Elisabetta and R. Ardito and S. Stecchi and C. Scandellari and Marrosu, {M. G.} and G. Spinicci and F. Patti and E. D'Amico and E. Portaccio and S. Lori and Costantino, {G. F.} and V. Pilato and M. Zaffaroni and A. Bellantonio and R. Fantozzi and C. Milanese and E. Scarpini and {De Riz}, M. and P. Sola and E. Merelli and A. Guerra and P. Perini and M. Atzori and R. Bergamaschi and P. Veggiottii and L. Prosperini and A. Bertolotto and M. Capobianco and S. Malucchi and P. Cavalla",
year = "2009",
doi = "10.1007/s10072-009-0083-1",
language = "English",
volume = "30",
pages = "193--199",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis

T2 - The Italian experience

AU - Ghezzi, Angelo

AU - Amato, Maria Pia

AU - Annovazzi, Pietro

AU - Capobianco, Marco

AU - Gallo, Paolo

AU - La Mantia, Loredana

AU - Marrosu, Maria Giovanna

AU - Martinelli, Vittorio

AU - Milani, Nicoletta

AU - Moiola, Lucia

AU - Patti, Francesco

AU - Pozzilli, Carlo

AU - Trojano, Maria

AU - Zaffaroni, Mauro

AU - Comi, Giancarlo

AU - Simone, I. L.

AU - Di Monte, Elisabetta

AU - Ardito, R.

AU - Stecchi, S.

AU - Scandellari, C.

AU - Marrosu, M. G.

AU - Spinicci, G.

AU - Patti, F.

AU - D'Amico, E.

AU - Portaccio, E.

AU - Lori, S.

AU - Costantino, G. F.

AU - Pilato, V.

AU - Zaffaroni, M.

AU - Bellantonio, A.

AU - Fantozzi, R.

AU - Milanese, C.

AU - Scarpini, E.

AU - De Riz, M.

AU - Sola, P.

AU - Merelli, E.

AU - Guerra, A.

AU - Perini, P.

AU - Atzori, M.

AU - Bergamaschi, R.

AU - Veggiottii, P.

AU - Prosperini, L.

AU - Bertolotto, A.

AU - Capobianco, M.

AU - Malucchi, S.

AU - Cavalla, P.

PY - 2009

Y1 - 2009

N2 - The main objective of this study is to evaluate the effect of immunomodulatory agents (IMAs) (Interferon-Beta, Glatiramer Acetate) in a large cohort of multiple sclerosis (MS) patients with disease onset in childhood or adolescence, treated before 16 years of age, after a long-term follow-up. A total of 130 patients were identified, 77 were treated with Avonex, 39 with Rebif/Betaferon, 14 with Copaxone. After a mean (SD) treatment duration of 53.6 ± 27.0, 59.9 ± 39.5 and 74.6 ± 35.5 months, respectively, the relapse rate decreased significantly. The final EDSS score was unchanged with respect to the initial score. Similar results were also observed in subjects who continued a long-term follow-up after they were included in an observational study in 2004, and in subjects who were treated before 12 years of age. The frequency of clinical and laboratory adverse events was similar to that observed in adult patients. To conclude, IMAs were effective and well tolerated in paediatric patients with MS.

AB - The main objective of this study is to evaluate the effect of immunomodulatory agents (IMAs) (Interferon-Beta, Glatiramer Acetate) in a large cohort of multiple sclerosis (MS) patients with disease onset in childhood or adolescence, treated before 16 years of age, after a long-term follow-up. A total of 130 patients were identified, 77 were treated with Avonex, 39 with Rebif/Betaferon, 14 with Copaxone. After a mean (SD) treatment duration of 53.6 ± 27.0, 59.9 ± 39.5 and 74.6 ± 35.5 months, respectively, the relapse rate decreased significantly. The final EDSS score was unchanged with respect to the initial score. Similar results were also observed in subjects who continued a long-term follow-up after they were included in an observational study in 2004, and in subjects who were treated before 12 years of age. The frequency of clinical and laboratory adverse events was similar to that observed in adult patients. To conclude, IMAs were effective and well tolerated in paediatric patients with MS.

KW - Adolescence

KW - Childhood

KW - Glatiramer acetate

KW - Immunomodulatory agents

KW - Interferon-beta

KW - Multiple sclerosis

KW - Paediatric multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=67349159369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349159369&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0083-1

DO - 10.1007/s10072-009-0083-1

M3 - Article

VL - 30

SP - 193

EP - 199

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -